Acylaminocycloalkyl compounds suitable for treating disorders that respond to modulation of dopamine d3 receptor

A compound of the formula I

• where
• m is 1 or 2,
• n is 1 or 2,
• A is selected from the group consisting of CH2, CH2CH2, CHFCH2 and CF2CH2,
• R1 is an oxygen containing cyclic radical selected from oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C6 cycloalkyl, which carries one or two oxygen containing radicals selected from the group consisting of OH, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, and a carbonyl oxygen, and which may additionally carry 1 or 2 radicals selected from fluorine, C1-C2-alkyl and fluorinated C1-C2-alkyl;
• R2 is selected from the group consisting of hydrogen and fluorine,
• R3a is selected from the group consisting of hydrogen and methyl,
• R3b is selected from the group consisting of hydrogen and methyl,
• R4 is branched C4-C6 alkyl or branched fluorinated C4-C6 alkyl, and
• R5 is selected from the group consisting of C1-C6 alkyl, fluorinated C1-C3 alkyl, C1-C2-alkoxy-C1-C4-alkyl, fluorinated C1-C2-alkoxy-C1-C4-alkyl, hydroxy-C1-C4-alkyl, fluorinated hydroxy-C1-C4-alkyl, oxetanyl, fluorinated oxetanyl, oxolanyl, fluorinated oxolanyl, C3-C5 cycloalkyl, fluorinated C3-C5 cycloalkyl, C3-C5 cycloalkyl-C1-C4-alkyl, fluorinated C3-C5 cycloalkyl-C1-C4-alkyl, C3-C5 cycloalkoxy-C1-C4-alkyl and fluorinated C3-C5 cycloalkoxy-C1-C4-alkyl, where the cycloalkyl moiety in the last six mentioned groups of radicals may carry 1 or 2 radicals selected from hydroxyl, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, C1-C2-alkyl and fluorinated C1-C2-alkyl, where the cycloalkoxy moiety in the last two mentioned radicals may carry 1 or 2 radicals selected from hydroxyl, C1-C2-alkoxy, fluorinated C1-C2-alkoxy, C1-C2-alkyl and fluorinated C1-C2-alkyl,
• the N-oxides, the prodrugs and the pharmaceutically acceptable salts of these compounds.